United Therapeutics (NASDAQ:UTHR) is scheduled to release its earnings data before the market opens on Wednesday, July 31st. Analysts expect United Therapeutics to post earnings of $2.39 per share for the quarter.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($13.96). United Therapeutics had a negative return on equity of 5.78% and a negative net margin of 9.36%. The company had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. During the same quarter in the previous year, the firm posted $3.76 EPS. The business’s revenue for the quarter was down 6.8% compared to the same quarter last year. On average, analysts expect United Therapeutics to post $-5 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Shares of NASDAQ:UTHR traded up $0.26 on Tuesday, hitting $78.46. 17,104 shares of the company were exchanged, compared to its average volume of 522,408. The firm’s 50 day moving average price is $78.16. United Therapeutics has a one year low of $74.31 and a one year high of $130.00. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.19 and a quick ratio of 6.84. The stock has a market capitalization of $3.43 billion, a price-to-earnings ratio of 5.85 and a beta of 1.04.

Several research firms have recently issued reports on UTHR. BidaskClub downgraded shares of Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Cowen restated a “hold” rating and set a $103.00 price objective on shares of United Therapeutics in a report on Wednesday, May 1st. UBS Group set a $25.00 price objective on shares of Macy’s and gave the stock a “hold” rating in a report on Friday, May 17th. Oppenheimer began coverage on shares of in a report on Tuesday, April 9th. They set an “outperform” rating and a $55.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating on shares of Purple Innovation in a report on Wednesday, May 8th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. United Therapeutics has a consensus rating of “Hold” and an average target price of $129.56.

In related news, Director Raymond Dwek sold 3,750 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $76.11, for a total value of $285,412.50. Following the sale, the director now owns 3,750 shares of the company’s stock, valued at $285,412.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard Giltner sold 5,000 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $79.05, for a total transaction of $395,250.00. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at approximately $395,250. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: Trading on Margin

Earnings History for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.